Galectin Therapeutics Inc. (GALT) — Financial statements
Income statement, balance sheet, and cash flow for Galectin Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.04↑12.1% | 0.03↑3.1% | 0.03↓22.0% | 0.04 | |
| Gross Profit | 0.00↑100.0% | -0.04↓12.1% | -0.03↓3.1% | -0.03↑22.0% | -0.04 | |
| Operating Expenses | ||||||
| R&D Expenses | 14↓60.9% | 37↑13.8% | 32↑1.2% | 32↑33.2% | 24 | |
| General & Administrative Expenses | 6 | 0.00↓100.0% | 6 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.04 | 0.00 | 0.00 | |
| SG&A Expenses | 6↓0.5% | 6↓2.0% | 6↓9.7% | 7↑4.2% | 6 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 20↓52.6% | 42↑11.5% | 38↓0.7% | 38↑27.1% | 30 | |
| Total Costs & Expenses | 20↓52.7% | 42↑11.5% | 38↓0.7% | 38↑27.1% | 30 | |
| Operating Results | ||||||
| Operating Income | -20↑52.7% | -42↓11.5% | -38↑0.7% | -38↓27.1% | -30 | |
| Depreciation & Amortization | 0.05↑43.2% | 0.04↑12.1% | 0.03↑3.1% | 0.03↓22.0% | 0.04 | |
| EBITDA | -23↑43.4% | -41↓8.4% | -38↓1.4% | -38↓25.7% | -30 | |
| EBIT | -24↑43.4% | -42↓8.4% | -38↓1.4% | -38↓25.7% | -30 | |
| Interest & Other Income | ||||||
| Net Interest Income | -7↓38.5% | -5↓103.0% | -3↓161.2% | -0.98↓101.9% | -0.49 | |
| Interest Income | 0.13↓62.7% | 0.34↑47.0% | 0.23↑342.3% | 0.05↑1633.3% | 0.00 | |
| Interest Expense | 7↑32.3% | 6↑98.4% | 3↑170.3% | 1↑111.2% | 0.49 | |
| Non-Operating Income | 3↑469.5% | -0.93↓558.4% | 0.20↑133.2% | -0.61↓331.9% | -0.14 | |
| Other Income / Expenses | -11↓133.0% | -5↓54.1% | -3↓606.1% | -0.42↓21.8% | -0.35 | |
| Income Before Tax | -31↑34.5% | -47↓14.6% | -41↓5.9% | -39↓27.0% | -31 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -31↑34.5% | -47↓14.6% | -41↓5.9% | -39↓27.0% | -31 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -31↑34.5% | -47↓14.6% | -41↓5.9% | -39↓27.0% | -31 | |
| Bottom-Line Net Income | -31↑34.7% | -47↓5.3% | -45↓15.3% | -39↓26.6% | -31 | |
| EPS (Basic) | -0.48↑36.8% | -0.76↓2.7% | -0.74↓13.8% | -0.65↓25.0% | -0.52 | |
| EPS (Diluted) | -0.48↑36.8% | -0.76↓2.7% | -0.74↓13.8% | -0.65↓25.0% | -0.52 | |
| Weighted Average Shares | 64↑2.6% | 62↑3.6% | 60↑1.3% | 59↑1.5% | 59 | |
| Weighted Average Diluted Shares | 64↑2.6% | 62↑3.6% | 60↑1.3% | 59↑1.5% | 59 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.